Low molecular weight heparin and the treatment of ischemic stroke. Animal results, the reasons for failure in human stroke trials, mechanisms of action, and the possibilities for future use in stroke.
Jonas
S
S
Department of Neurology, NYU School of Medicine, Bellevue Hospital Center, Rm. 7W-11, 462 First Avenue, New York, NY 10016, USA. saran.jonas@med.nyu.edu
Quartermain
D
D
D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002544:Cerebral Infarction / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D017984:Enoxaparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D009553:Nimodipine / Q000627:therapeutic use
D000925:Anticoagulants; D002121:Calcium Channel Blockers; D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight; D009553:Nimodipine; D002118:Calcium